In a 26-0 vote, the Senate Finance Committee Nov. 8 reported the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act, bipartisan legislation that includes AHA-supported provisions to improve access to behavioral health care and delay Medicaid disproportionate share hospital reductions.

The AHA-supported provisions would provide Medicare incentives to integrate behavioral health and primary care; delay certain Medicaid disproportionate share hospital payment reductions for two years; and permanently grant state Medicaid programs the option to receive federal matching payments for substance use disorder treatment provided in certain institutions for mental diseases. The legislation also would ensure timely communication regarding telehealth and interstate licensure requirements, and extend certain Medicare payment provisions for physicians and clinical laboratory services.

Headline
The AHA submitted a statement for the record to the House Ways and Means Committee for its April 28 hearing with health system CEOs.In the statement, the AHA…
Headline
The Food and Drug Administration today announced it is accelerating regulatory action on a new class of psychedelic-based therapies, following an April 18…
Headline
The Senate April 23 adopted a budget resolution by a 50-48 vote, paving the way for a narrow reconciliation bill focused on immigration enforcement funding.…
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…
Headline
Americans across 43 states enrolled in health plans from the nation’s four largest commercial health insurers face potential disparities in finding in-network…
Headline
David Stark, chief of government and external affairs and philanthropy officer at UnityPoint Health, shares how a major philanthropic investment is helping…